Abbott India FY26 Results: Profit Reaches ₹1,552 Crore, ₹656 Dividend Proposed

Abbott India Ltd. has reported strong financial performance for the fiscal year ending March 31, 2026.

What Happened

The company's Board of Directors met on May 11, 2026, approving the audited financial results for the fiscal year. Abbott India reported revenue from operations of ₹6,929.05 crore and Profit Before Tax (PBT) of ₹2,079.27 crore. Profit After Tax (PAT) for FY26 stood at ₹1,552.02 crore.

The board recommended a final dividend of ₹525 per share and a special dividend of ₹131 per share, totaling ₹656 per equity share. Additionally, Kishore Bhatia & Associates were appointed as Cost Auditors for FY 2026-27, pending shareholder ratification at the upcoming Annual General Meeting (AGM).

Why This Matters

The strong financial performance enables a substantial dividend payout, reflecting the company's profitability and commitment to shareholder value. Investors will monitor the impact of the ₹18.10 crore incremental cost due to new labour codes, which may require future accounting adjustments. The cost auditor appointment ensures compliance and transparency in cost accounting practices.

Company Background

Abbott India, a subsidiary of global healthcare firm Abbott Laboratories, USA, is a key player in India's healthcare sector, active in diagnostics, medical devices, nutritionals, and pharmaceuticals. In the previous fiscal year, FY25, Abbott India reported a PAT of approximately ₹1,250 crore on revenues around ₹6,100 crore, showing healthy year-on-year growth for FY26. Abbott India is known for consistent dividend payouts. For FY24, it declared a record dividend of ₹1000 per share. The FY26 recommended payout of ₹656 per share is a significant return.

What Changes Now

Shareholders will vote on the recommended ₹656 per share dividend at the AGM on August 13, 2026. The cost auditor appointment requires ratification by the company's members. Management will monitor the finalization of Central and State rules for the new Labour Codes, which could lead to future accounting adjustments.

Risks to Watch

A key risk involves further accounting adjustments stemming from the ongoing finalization of new Labour Codes. The company has already booked an incremental cost of ₹18.10 crore for FY26 related to employee benefits from these codes.

Peer Comparison

Major Indian pharmaceutical peers, including Sun Pharmaceutical Industries Ltd., Cipla Ltd., and Dr. Reddy's Laboratories Ltd., also have dividend policies. While Sun Pharma and Dr. Reddy's are larger, Abbott India's recommended ₹656 per share dividend for FY26 represents a substantial return, comparable to its historical payouts.

Key Financial Metrics (FY26)

• Revenue from operations for FY26 stood at ₹6,929.05 crore.
• Profit After Tax for FY26 was ₹1,552.02 crore.
• The Net Profit Margin for FY26 was approximately 22.39%.
• A total dividend of ₹656 per share has been recommended for FY26.

What to Track Next

Investors will track performance in the first quarter of FY27, focusing on revenue growth and margin trends. Management commentary on future growth drivers and dividend sustainability will also be key.